# Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment

> **NCT00165399** · PHASE2 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 62 (actual)

## Conditions studied

- Adenocarcinoma of the Prostate
- Prostate Cancer

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** Estramustine
- **DRUG:** Casodex
- **DRUG:** Zoladex

## Key facts

- **NCT ID:** NCT00165399
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03
- **Primary completion:** 2005-12-31
- **Final completion:** 2005-12-31
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2018-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00165399

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00165399, "Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT00165399. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*